Ulcerative Colitis Treatment Patterns and Cost of Care

Abstract

Objectives: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). Methods: This retrospective cohort study identified the first pharmacy or medical claim for ADA or IFX (from January 1, 2007, to December 31, 2014) in patients with continuous enrollment for 6 months or more preindex and 12 months or more postindex, with one or more UC diagnosis claim 6 months pre-or postindex. TNFi discontinuation was defined as a therapy gap of 56 days or more for ADA and 112 days or more for IFX. TNFi switch was defined as nonindex TNFi initiation. Health care resource utilization and costs were characterized quarterly according to treatment patterns. Results: The study population comprised 295 patients: mean age 50.9 years, 50.5% females, and 61.7% in southern United States. At the index date, 17% of patients received ADA and 83% received IFX. Treatment discontinuation was observed in 52% of ADA and 45% of IFX users through 12 months postindex (mean time 19 and 22 weeks, respectively). Among discontinuers, 46% of ADA and 68% of IFX users did not restart/switch TNFi. ADA and IFX showed mean times to switch of 18 and 30 weeks, respectively. TNFi discontinuers had the lowest mean quarterly total health care cost ($3,935) versus patients who initiated/switched TNFi ($15,004). Nevertheless, discontinuers had higher UC-related hospitalization versus patients receiving therapy.Conclusions: Approximately half of ADA and IFX users discontinued, with approximately half of discontinuers not restarting/switching therapies. Further investigation of treatment patterns and outcomes after TNFi discontinuation is required.

Real-World Prescription Pattern and Healthcare Cost Among Patients with Ulcerative Colitis in Japan: A Retrospective Claims Data Analysis

“…The median duration of biologic treatment among treatment-naïve patients in the current study was 7.2 months, and 64.5% of those who received biologics discontinued after 1 year. Null et al, in a retrospective analysis of US health claims data, reported that about 50% of patients receiving infliximab or adalimumab discontinued during the first 12 months, and a substantial percentage of those patients did not restart or switch to another biologic therapy [ 29 ]. The reasons for discontinuation, though poorly understood, may include side effects or a lack of efficacy [ 30 ], although the reasons for discontinuation were unavailable in our study.…”

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study

“…One retrospective database study of TNF inhibitor use reported 12-month discontinuation rates with adalimumab and infliximab of 52% and 45%, respectively. 34 …”

The protective effect of nigeglanine on dextran sulfate sodium‐induced experimental colitis in mice and Caco‐2 cells

“…The results of the histopathological analysis showed that the DSSinduced pathological changes were significantly improved by nigeglanine treatment. ZO-1 and occludin levels were significantly reduced during the progression of DSS-induced UC; however, upon have attracted increasing attention with regards to the prevention and control of many diseases, especially digestive diseases (Null et al, 2017).…”